Aeterna Zentaris, Inc. (NASDAQ: AEZS) is a specialty biopharmaceutical company engaged in the development and commercialization of novel treatments in the fields of oncology, endocrinology and women’s health. The company’s product pipeline includes Macrilen™, which is currently in phase III clinical testing for the diagnosis of adult growth hormone deficiency, as well as zoptarelin doxorubicin, which is in phase III clinical development for the treatment of endometrial cancer. For more information, visit the company’s website at www.aezsinc.com.